Alzamend Neuro, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc. (ALZN) on August 5, 2022. The report discloses material events regarding the departure of a senior officer and the appointment of a new Chief Financial Officer.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance changes.
Material Changes
- Resignation: Lien Escalona resigned as Chief Financial Officer (CFO) effective August 1, 2022.
- Appointment: David J. Katzoff was appointed as the new Chief Financial Officer on August 5, 2022.
- Background: Mr. Katzoff previously served as the Company's Chief Operating Officer (December 2020 to August 2022) and Senior Vice President of Operations (November 2019 to December 2020).
Management Commentary and Compensation
Mr. Katzoff brings extensive experience from other public companies, including roles as CFO for Imperalis Holding Corp. and BitNile Holdings, Inc. The filing states there are no family relationships between Mr. Katzoff and other directors or officers. There are no employment agreements in place for Mr. Katzoff, and no changes are currently being made to his compensation. No arrangements or understandings requiring disclosure under Item 404(a) of Regulation S-K exist.
Investor Verification Checklist
- Verify the effective date of Lien Escalona's resignation (August 1, 2022).
- Confirm David J. Katzoff's new title and start date as CFO (August 5, 2022).
- Note the absence of a formal employment agreement for the new CFO.
- Review Mr. Katzoff's concurrent roles at other public entities (Imperalis Holding Corp., BitNile Holdings, Inc., Ault Disruptive Technologies Corporation).